47.16
0.65 (1.40%)
| Previous Close | 46.51 |
| Open | 46.96 |
| Volume | 492,606 |
| Avg. Volume (3M) | 853,159 |
| Market Cap | 2,704,123,904 |
| Price / Earnings (Forward) | 20.16 |
| Price / Sales | 4.25 |
| Price / Book | 2.81 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | 9.27% |
| Operating Margin (TTM) | -4.67% |
| Diluted EPS (TTM) | 1.11 |
| Quarterly Revenue Growth (YOY) | 4.30% |
| Quarterly Earnings Growth (YOY) | 1,204.50% |
| Total Debt/Equity (MRQ) | 3.13% |
| Current Ratio (MRQ) | 2.44 |
| Operating Cash Flow (TTM) | 164.15 M |
| Levered Free Cash Flow (TTM) | 138.80 M |
| Return on Assets (TTM) | 2.76% |
| Return on Equity (TTM) | 6.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Supernus Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -2.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 4.11% |
| % Held by Institutions | 109.15% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 65.00 (B of A Securities, 37.83%) | Buy |
| 65.00 (Piper Sandler, 37.83%) | Buy | |
| Median | 63.00 (33.59%) | |
| Low | 55.00 (Stifel, 16.62%) | Hold |
| Average | 61.60 (30.62%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 51.30 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 19 Dec 2025 | 55.00 (16.62%) | Hold | 51.48 |
| B of A Securities | 29 Oct 2025 | 65.00 (37.83%) | Buy | 55.68 |
| TD Cowen | 23 Oct 2025 | 60.00 (27.23%) | Buy | 52.02 |
| Piper Sandler | 09 Oct 2025 | 65.00 (37.83%) | Buy | 49.51 |
| Cantor Fitzgerald | 30 Sep 2025 | 63.00 (33.59%) | Buy | 47.79 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BHATT PADMANABH P. | - | 49.28 | -710 | -34,989 |
| MOTTOLA FRANK | - | 51.48 | -20,000 | -1,029,600 |
| Aggregate Net Quantity | -20,710 | |||
| Aggregate Net Value ($) | -1,064,589 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 50.38 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MOTTOLA FRANK | Officer | 19 Dec 2025 | Automatic sell (-) | 20,000 | 51.48 | 1,029,600 |
| MOTTOLA FRANK | Officer | 19 Dec 2025 | Option execute | 20,000 | - | - |
| BHATT PADMANABH P. | Officer | 18 Dec 2025 | Sell (-) | 710 | 49.28 | 34,989 |
| BHATT PADMANABH P. | Officer | 18 Dec 2025 | Option execute | 1,500 | - | - |
| Date | Type | Details |
|---|---|---|
| 03 Dec 2025 | Announcement | Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference |
| 21 Nov 2025 | Announcement | Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference |
| 12 Nov 2025 | Announcement | Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London |
| 04 Nov 2025 | Announcement | Supernus Announces Third Quarter 2025 Financial Results |
| 21 Oct 2025 | Announcement | Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |